GLPwatch
Papers (9189)
Page 71 of 154, ranked by citation count.
- IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes.
- The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting.
- Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin.
- Allocation of Semaglutide According to Coronary Artery Calcium and BMI: Applying the SELECT Trial to MESA.
- Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial.
- Effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on abdominal fat distribution in people with obesity and type 2 diabetes mellitus evaluated by the energy spectrum ct: A prospective randomized controlled study.
- Improved Localization of Insulinomas Using <sup>68</sup>Ga-NODAGA-Exendin-4 PET/CT.
- A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders.
- Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta-analysis.
- Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.
- The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists.
- Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial.
- Cardiovascular outcomes and safety with antidiabetic drugs.
- Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.
- Glutamatergic Alterations in STZ-Induced Diabetic Rats Are Reversed by Exendin-4.
- Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.
- Optimization of Enzymolysis Clearance Strategy To Enhance Renal Clearance of Radioligands.
- Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
- Hypothalamic obesity after craniopharyngioma surgery: Treatment with a long acting glucagon like peptide 1 derivated.
- GLP-1 preserves β cell function via improvement on islet insulin signaling in high fat diet feeding mice.
- Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial.
- Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
- Total Synthesis of Semaglutide Based on a Soluble Hydrophobic-Support-Assisted Liquid-Phase Synthetic Method.
- Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice.
- Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.
- Liraglutide Attenuates Glucolipotoxicity-Induced RSC96 Schwann Cells' Inflammation and Dysfunction.
- Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY<sub>3-36</sub> Combination Therapy in Diet-Induced Obese Rats.
- Exenatide reverses dysregulated microRNAs in high-fat diet-induced obese mice.
- Hypoglycemic drug liraglutide alleviates low muscle mass by inhibiting the expression of MuRF1 and MAFbx in diabetic muscle atrophy.
- Long-term feeding on powdered food causes hyperglycemia and signs of systemic illness in mice.
- Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies.
- Peptide ligations accelerated by N-terminal aspartate and glutamate residues.
- What is known about the use of weight loss medication in women with overweight/obesity on fertility and reproductive health outcomes? A scoping review.
- Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study.
- GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.
- Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States : A Population-Based Cohort Study.
- Pharmacotherapy for obesity.
- Combination therapies for type 1 diabetes: why not now?
- Evaluation of the efficacy of low-dose liraglutide in weight control among Taiwanese non-diabetes patients.
- Thermal stability of exenatide encapsulated in stratified dissolving microneedles during storage.
- Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects.
- Liraglutide abrogates nephrotoxic effects of chemotherapies.
- GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes.
- Semaglutide Modulates Extracellular Matrix Production of LX-2 Cells via Exosomes and Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
- Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).
- Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well-controlled type 2 diabetes: A 24-week randomized controlled trial.
- Hepatic portal vein denervation impairs oral glucose tolerance but not exenatide's effect on glycemia.
- Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential.
- Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection.
- Cardioprotective effects of semaglutide on isolated human ventricular myocardium.
- Role of glucagon-like peptide-1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts.
- Novel double-layered PLGA microparticles-dissolving microneedle (MPs-DMN) system for peptide drugs sustained release by transdermal delivery.
- Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists.
- The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus-A Systematic Review.
- Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects.
- Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway.
- Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naïve type 2 diabetic patients.
- Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity.
- Adherence and treatment discontinuation of oral semaglutide and once-weekly semaglutide injection at 12 month follow-up: Japanese real-world data.
- Glutamine up-regulates pancreatic sodium-dependent neutral aminoacid transporter-2 and mitigates islets apoptosis in diabetic rats.